| |
Group I (AmB+
|
Group II (AmB +
|
P-value
|
|---|
|
Fluconazole+ 5-FC,n = 27)
|
Fluconazole+ 5-FC + VPS, na = 38)
|
|---|
|
case (n, %)
|
8 (29.6%)
|
22 (56.4%)
|
0.033*
|
|
Daysb (mean ± SD)
|
29.2 ± 20.0
|
32.5 ± 24.8
|
0.909
|
|
≤ 2 weeks (n, %)
|
2 (7.4%)
|
8 (20.5%)
|
0.662
|
|
> 2 weeks (n, %)
|
6 (22.2%)
|
14 (35.9%)
| |
|
≤ 4 weeks (n, %)
|
4 (14.8%)
|
13 (33.3%)
|
0.730
|
|
> 4 weeks (n, %)
|
4 (14.8%)
|
9 (23.1%)
| |
- AmB amphotericin B, 5-Fc flucytosine, Flu fluconazole, SD standard deviation. Continuous variables analyzed by t-test; categorical variables analyzed by chi-square test or Fisher’s exact test
- a One patient was lost to -follow-up at the 10th week in Group II
- b‘Days’ indicates the time from diagnosis to the first negative CSF india ink stain
- *P < 0.05
